rhenium has been researched along with Dysmyelopoietic Syndromes in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (80.00) | 29.6817 |
| 2010's | 1 (20.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bornhäuser, M; Ehninger, G; Kotzerke, J; Schetelig, J; Schneider, S; Strumpf, A; Wunderlich, G | 1 |
| Buchmann, I; Bunjes, D; Mutschler, J; Reske, SN; Steinbach, G | 1 |
| Bartkowiak, D; Bunjes, D; Dohr, D; Röttinger, EM; Wennauer, R | 1 |
| Blumstein, N; Buchmann, I; Buck, AK; Bunjes, D; Döhner, H; Glatting, G; Kotzerke, J; Neumaier, B; Reske, SN; Ringhoffer, M; Schauwecker, P; Stilgenbauer, S; von Harsdorf, S; Wiesneth, M; Zenz, T | 1 |
| Bergmann, L; Buchmann, I; Buck, A; Bunjes, D; Döhner, H; Dohr, D; Duncker, C; Glatting, G; Grimminger, W; Harsdorf, SV; Karakas, T; Kotzerke, J; Munzert, G; Reske, SN; Seitz, U; Stefanic, M; Wiesneth, M | 1 |
3 trial(s) available for rhenium and Dysmyelopoietic Syndromes
| Article | Year |
|---|---|
Reduced-Intensity Conditioning Combined with (188)Rhenium Radioimmunotherapy before Allogeneic Hematopoietic Stem Cell Transplantation in Elderly Patients with Acute Myeloid Leukemia: The Role of In Vivo T Cell Depletion.
Topics: Aged; Alemtuzumab; Allografts; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antigens, CD; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cell Adhesion Molecules; Combined Modality Therapy; Disease-Free Survival; Dose-Response Relationship, Drug; Feasibility Studies; Female; Graft vs Host Disease; Graft vs Leukemia Effect; Humans; Immunoconjugates; Leukemia, Myeloid, Acute; Lymphocyte Depletion; Male; Middle Aged; Myelodysplastic Syndromes; Neutropenia; Prospective Studies; Radioimmunotherapy; Radioisotopes; Rhenium; T-Lymphocytes; Transplantation Conditioning; Vidarabine | 2015 |
188Re or 90Y-labelled anti-CD66 antibody as part of a dose-reduced conditioning regimen for patients with acute leukaemia or myelodysplastic syndrome over the age of 55: results of a phase I-II study.
Topics: Aged; Antibodies, Monoclonal; Antigens, CD; Antigens, Differentiation; Antilymphocyte Serum; Antineoplastic Agents; Cell Adhesion Molecules; Female; Follow-Up Studies; Hematologic Diseases; Humans; Immunosuppressive Agents; Leukemia; Lymphocyte Depletion; Male; Melphalan; Middle Aged; Myelodysplastic Syndromes; Radioimmunotherapy; Radioisotopes; Radiometry; Rhenium; Stem Cell Transplantation; Survival Rate; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Yttrium Radioisotopes | 2005 |
Rhenium 188-labeled anti-CD66 (a, b, c, e) monoclonal antibody to intensify the conditioning regimen prior to stem cell transplantation for patients with high-risk acute myeloid leukemia or myelodysplastic syndrome: results of a phase I-II study.
Topics: Acute Disease; Adolescent; Adult; Antibodies, Monoclonal; Antigens, CD; Antigens, Differentiation; Cell Adhesion Molecules; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid; Lymphocyte Depletion; Male; Middle Aged; Myelodysplastic Syndromes; Radioimmunotherapy; Radioisotopes; Rhenium; Risk Factors; T-Lymphocytes; Transplantation Conditioning; Treatment Outcome | 2001 |
2 other study(ies) available for rhenium and Dysmyelopoietic Syndromes
| Article | Year |
|---|---|
[Myeloablative radioimmunotherapy with 188Re-CD66mAb before stem cell transplantation. No increase of proinflammatory cytokine levels of TNF-alpha].
Topics: Adult; Antibodies, Monoclonal; Antigens, CD; Cell Adhesion Molecules; Child; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Radioimmunotherapy; Radioisotopes; Rhenium; Stem Cell Transplantation; Tumor Necrosis Factor-alpha; Young Adult | 2009 |
Enhanced renal toxicity of total body irradiation combined with radioimmunotherapy.
Topics: Adolescent; Adult; Animals; Creatinine; Dose Fractionation, Radiation; Female; Follow-Up Studies; Graft vs Host Disease; Humans; Kidney; Leukemia; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Radiation Dosage; Radioimmunotherapy; Radioisotopes; Radiotherapy Dosage; Rats; Rhenium; Stem Cell Transplantation; Time Factors; Whole-Body Irradiation | 2003 |